Corpus ID: 46370969

Monitoring Of Blood L-DOPA And L-DOPA Metabolite Concentrations And Adverse Events In Patients With Advanced Parkinsons Disease Receiving L-DOPA And Amantadine Combination Therapy: A Clinical Study

@article{Satoh2015MonitoringOB,
  title={Monitoring Of Blood L-DOPA And L-DOPA Metabolite Concentrations And Adverse Events In Patients With Advanced Parkinsons Disease Receiving L-DOPA And Amantadine Combination Therapy: A Clinical Study},
  author={M. Satoh and Ami Kuzuu and H. Doi and Toru Masaka and R. Sakakibara},
  journal={Research & Reviews: Journal of Pharmacy and Pharmaceutical Sciences},
  year={2015},
  volume={4}
}

M. Satoh, Ami Kuzuu, +2 authors R. Sakakibara

Published 2015

Medicine

Research & Reviews: Journal of Pharmacy and Pharmaceutical Sciences

As L-DOPA replacement is the main treatment for patients with Parkinson’s disease, monitoring of the blood dopamine (DA) concentration is useful for prediction of peripheral adverse events. We studied patients with advanced Parkinson’s disease for whom L-DOPA and an NMDA receptor antagonist, amantadine, had been prescribed since 2006 at Sakura Hospital, Toho University Medical Center. The blood concentrations of L-DOPA, DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-O-methyldopa (3-OMD… CONTINUE READING

rroij.com

Save to Library

Create Alert

Cite

Launch Research Feed